The data are from the National Health Insurance Research Database (NHIRD) Committee and can be contacted at the following email: <nhird@nhri.org.tw>.

Introduction {#sec005}
============

In the United States, diabetes is one of the leading causes of adult death and disability. It also represents a large and rapidly growing economic burden, with an estimated cost of US\$245 billion in 2012 \[[@pone.0181815.ref001],[@pone.0181815.ref002]\]. Although diabetes' epidemiology, pathogenesis, treatment guidelines and prevention programs have been well established over 204 years \[[@pone.0181815.ref003]\], it remains a pandemic disease that will reach an estimated global prevalence of 4.4% by 2030 \[[@pone.0181815.ref004]\].

Type 2 diabetes is considered a common comorbidity for patients with chronic obstructive pulmonary disease (COPD) and reduced lung function \[[@pone.0181815.ref005]--[@pone.0181815.ref010]\]. Epidemiological investigations show that diabetes is much more likely in patients with COPD than in control subjects \[[@pone.0181815.ref011],[@pone.0181815.ref012]\]. A controversial population-based study using an Italian database found patients with COPD had an increased risk for diabetes compared to non-COPD subjects \[[@pone.0181815.ref013],[@pone.0181815.ref014]\].

Although the association between COPD and diabetes risk was reported in previous studies \[[@pone.0181815.ref011]--[@pone.0181815.ref016]\], the risk of diabetes for COPD patients in previous studies were limited by cross-sectional study design \[[@pone.0181815.ref011]--[@pone.0181815.ref014]\], lack of adequate control subjects \[[@pone.0181815.ref011]--[@pone.0181815.ref014]\], poor adjustment for potential confounders \[[@pone.0181815.ref015],[@pone.0181815.ref016]\], short follow-up and incorrect selection of COPD cases \[[@pone.0181815.ref015]\]. The impact of COPD exacerbations on diabetic patients' risk and outcomes is also unclear.

Based on the context described above, we hypothesized that patients with COPD may have increased the risk and adverse outcomes of diabetes. Using claims data from Taiwan's National Health Research Database \[[@pone.0181815.ref006],[@pone.0181815.ref007]\], we conducted a nationwide longitudinal cohort study to assess the risks of diabetes, post-diabetes mortality and complications in patients with COPD.

Methods {#sec006}
=======

Source of data {#sec007}
--------------

Reimbursement claims used in this study were collected from the National Health Insurance Research Database. This insurance program was implemented in March 1995 and covers more than 99% of Taiwan's 23 million residents. The National Health Research Institutes established this database to record beneficiaries' medical services, including inpatient and outpatient demographic characteristics, physicians' primary and secondary diagnoses, treatment procedures, prescriptions and medical expenditures. Research articles based on this database have been accepted in prominent scientific journals worldwide \[[@pone.0181815.ref006],[@pone.0181815.ref007]\]. To protect personal privacy, the database was decoded and patient identifications were scrambled for further public access for this research. This study was evaluated and approved by the Joint Institutional Review Board of Taipei Medical University (TMU-JIRB-201605049) and E-DA Hospital (EDA-JIRB-2017004).

Study design and population {#sec008}
---------------------------

We used the National Health Insurance Research Database to perform two nationwide, population-based retrospective cohort studies. Using the database's representative sample of one million beneficiaries, we conducted a retrospective cohort study of 9,342 COPD patients without exacerbations and 4671 patients with newly diagnosed COPD exacerbations with frequency matching by age and sex (COPD: COPDe = 2:1). We defined COPD patients as follows: people had at least two medical visits for outpatient care with physician's primary diagnosis of COPD within one year. We defined patients with COPD exacerbations as follows: people received physician's care due to COPD in the hospitalization ward or emergency room These definitions of COPD and COPD exacerbations were based on previous reports \[[@pone.0181815.ref017]--[@pone.0181815.ref019],[@pone.0181815.ref020],[@pone.0181815.ref021]\]. For comparison, 18,684 frequency-matched individuals without COPD were selected (controls: COPDe = 4:1). These three cohorts, with subjects aged ≥40 years, were established between January 1, 2000, and December 31, 2005, and then followed until December 31, 2013. We calculated person-years during the follow-up period for each participant until diagnosis of diabetes or until censored because of death, withdrawal from the insurance system, or loss to follow-up. The non-COPD group included the remaining people who did not develop COPD during the follow-up period.

Using a diabetes cohort consisting of all incident diabetes patients among the total population of 23 million people from the National Health Insurance Research Database, we identified 395,516 new-onset diabetes patients hospitalized during 2000--2013. We compared sociodemographics, co-morbidities and medications for diabetes patients with no COPD, COPD, and COPDe. Risks of pneumonia, intensive care and mortality during diabetes admission were also estimated.

Measures and definition {#sec009}
-----------------------

We identified income status and defined low-income patients as those qualifying for waived medical copayment, which was verified by the Bureau of National Health Insurance. *The International Classification of Diseases*, *Ninth Revision*, *Clinical Modification* (ICD-9-CM) was used to define chronic obstructive pulmonary disease (ICD-9-CM 491, 492, 496) \[[@pone.0181815.ref017],[@pone.0181815.ref018]\], diabetes (ICD-9-CM 250), co-morbidities and post-diabetes complications. Co-morbidities included hypertension (ICD-9-CM 401--405), mental disorders (ICD-9-CM 290--319), ischemic heart disease (ICD-9-CM 410--414), stroke (ICD-9-CM 430--438), liver cirrhosis (ICD-9-CM 571), hyperlipidemia (ICD-9-CM 272.0, 272.1, and 272.2), heart failure (ICD-9-CM 428), anemia (ICD-9-CM 280--285), Parkinson's disease (ICD-9-CM 332), atrial fibrillation (ICD-9-CM 427.31), and peripheral vascular disease (ICD-9-CM 443). Renal dialysis was identified by administration code (D8, D9). In-hospital 30-day mortality after the index diabetes admission was considered the primary outcome, and post-diabetes pneumonia (ICD-9-CM 480--486), intensive care, length of hospital stay and medical expenditure were considered secondary outcomes in the nested cohort study. We also considered the impact of invasive respiratory treatments on diabetes risk and outcomes, and these treatments included endotracheal tube insertion, tracheal stent insertion, tracheostomy, laryngotracheal reconstruction, repair of tracheobronchial tree, and endobronchial dilatation.

Statistical analyses {#sec010}
--------------------

Using the analysis of chi-square tests, we compared sociodemographic factors (such as age, sex and low income), co-morbidities (such as hypertension, mental disorders, liver cirrhosis, stroke, hyperlipidemia, heart failure, anemia, atrial fibrillation, peripheral vascular disease and renal dialysis), and medications (such as anticoagulant, anti-platelet agents and lipid-lowering agents) for people with no COPD, with COPD or with COPDe. The adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of diabetes associated with COPDe were calculated using multivariate Cox proportional hazard models. In the further stratified analysis, the adjusted HRs and 95% CIs of diabetes associated with COPD or COPDe were also calculated in both sexes and all age groups.

In the nested cohort study, analysis of chi-square tests compared differences in sociodemographics, co-morbidities and medications for diabetes patients in the three groups. By using multivariate logistic regressions, we calculated adjusted odds ratios (ORs) and 95% CIs for risks of pneumonia, intensive care and mortality after diabetes. The mean length of stay and medical expenditure were also compared by analysis of variance for diabetic patients without COPD or with COPD or COPDe.

Results {#sec011}
=======

After matching by age and sex among cohorts without COPD, with COPD and COPDe, proportionately more patients with COPDe had low-income status, hypertension, mental disorders, ischemic heart disease, stroke, liver cirrhosis, hyperlipidemia, heart failure, anemia, Parkinson's disease, atrial fibrillation, peripheral vascular disease and renal dialysis, compared with people without COPD (p\<0.0001). Use of medications such as anticoagulants, anti-platelet agents and lipid-lowering agents was also higher in patients with COPDe than in those without COPD ([Table 1](#pone.0181815.t001){ref-type="table"}) (p\<0.0001).

10.1371/journal.pone.0181815.t001

###### Baseline characteristics of people with and without COPD.

![](pone.0181815.t001){#pone.0181815.t001g}

                                 No COPD N = 18684   COPD N = 9342   COPDe N = 4671   *P* value                   
  ------------------------------ ------------------- --------------- ---------------- ----------- ------ -------- ----------
  Sex                            n                   (%)             n                (%)         n      (%)      1.0000
   Female                        9256                (49.5)          4628             (49.5)      2314   (49.5)   
   Male                          9428                (50.5)          4714             (50.5)      2357   (50.5)   
  Age, years                                                                                                      1.0000
   40--49                        5064                (27.1)          2532             (27.1)      1266   (27.1)   
   50--59                        5292                (28.3)          2646             (28.3)      1323   (28.3)   
   60--69                        5744                (30.7)          2872             (30.7)      1436   (30.7)   
   70--79                        2584                (13.8)          1292             (13.8)      646    (13.8)   
  Low income                     289                 (1.6)           295              (3.2)       231    (5.0)    \<0.0001
  Co-morbidities                                                                                                  
   Hypertension                  8667                (46.4)          5405             (57.9)      2803   (60.0)   \<0.0001
   Mental disorder               5296                (28.4)          4225             (45.2)      2213   (47.4)   \<0.0001
   Ischemic heart disease.       3140                (16.8)          2900             (31.0)      1621   (34.7)   \<0.0001
   Stroke                        2941                (15.7)          2095             (22.4)      1324   (28.4)   \<0.0001
   Liver cirrhosis               3316                (17.8)          2628             (28.1)      1151   (24.6)   \<0.0001
   Hyperlipidemia                3948                (21.1)          2841             (30.4)      1142   (24.5)   \<0.0001
   Heart failure                 511                 (2.7)           612              (6.6)       555    (11.9)   \<0.0001
   Anemia                        1139                (6.1)           858              (9.2)       416    (8.9)    \<0.0001
   Parkinson\'s disease          355                 (1.9)           245              (2.6)       166    (3.6)    \<0.0001
   Atrial fibrillation           209                 (1.1)           236              (2.5)       161    (3.5)    \<0.0001
   Peripheral vascular disease   399                 (2.1)           331              (3.5)       156    (3.3)    \<0.0001
   Renal dialysis                232                 (1.2)           131              (1.4)       117    (2.5)    \<0.0001
  Anticoagulants                 540                 (2.9)           450              (4.8)       307    (6.6)    \<0.0001
  Anti-platelet agents           7884                (42.2)          5461             (58.5)      2965   (64.5)   \<0.0001
  Lipid-lowering agents          5660                (30.3)          3732             (40.0)      1877   (40.2)   \<0.0001

COPD = chronic obstructive pulmonary disease; COPDe = chronic obstructive pulmonary disease with exacerbations.

[Table 2](#pone.0181815.t002){ref-type="table"} shows a higher incidence of diabetes in patients with previous COPD and COPDe than those without COPD (4.1 and 7.4 vs. 3.4 per 1000 person-years, p\<0.0001) during the follow-up period. The corresponding HRs for diabetes associated with COPD or COPDe were 1.09 (95% CI, 1.02--1.17) and 2.18 (95% CI, 1.88--2.52), respectively. The association between COPDe and diabetes risk was significant in females (HR, 2.11; 95% CI, 1.72--2.58), males (HR, 2.27; 95% CI, 1.83--2.82) and people in all age groups, specifically 40--49 years (HR, 3.73; 95% CI, 2.41--5.79), 50--59 years (HR, 2.88; 95% CI, 2.16--3.86), 60--69 years (HR, 1.71; 95% CI, 1.35--2.16) and 70--79 years (HR, 1.73; 95% CI, 1.23--2.42). HRs for diabetes risk associated with COPDe for people with 0, 1, 2, ≥3 co-morbidities were 2.68 (95% CI 1.74--4.11), 2.52 (95% CI 1.86--3.42), 2.19 (95% CI 1.65--2.90) and 1.81 (95% CI 1.45--2.26) respectively. Compared with the non-COPD cohort or the COPD cohort ([Fig 1](#pone.0181815.g001){ref-type="fig"}), patients with COPDe showed a significantly increased probability of developing diabetes during the follow-up years (log-rank test, p\<0.0001). The diabetes risk associated with respiratory invasive treatment for patients with COPDe (HR 1.47, 95% CI 0.95--2.52) was not significant.

10.1371/journal.pone.0181815.t002

###### Risk of diabetes for patients with and without COPD by sex and age.

![](pone.0181815.t002){#pone.0181815.t002g}

                                                                    n       Events   Person-years   Incidence[^b^](#t002fn003){ref-type="table-fn"}   HR             (95% CI)[^a^](#t002fn002){ref-type="table-fn"}
  ------------------------------------------------------- --------- ------- -------- -------------- ------------------------------------------------- -------------- ------------------------------------------------
  No COPD                                                           18684   563      167874         3.4                                               1.00           (reference)
  COPD                                                              9342    360      87209          4.1                                               1.09           (1.02--1.17)
  COPDe                                                             4671    308      41658          7.4                                               2.18           (1.88--2.52)
  COPDe treatment[^c^](#t002fn004){ref-type="table-fn"}             646     23       3289           7.0                                               1.47           (0.95--2.26)
  Female                                                  No COPD   9256    302      85915          3.5                                               1.00           (reference)
  COPD                                                    4628      188     43903    4.3            1.08                                              (0.99--1.19)   
  COPDe                                                   2314      162     21576    7.5            2.11                                              (1.72--2.58)   
  Male                                                    No COPD   9428    261      81959          3.2                                               1.00           (reference)
  COPD                                                    4714      172     43306    4.0            1.10                                              (0.99--1.22)   
  COPDe                                                   2357      146     20082    7.3            2.27                                              (1.83--2.82)   
  40--49 years                                            No COPD   5064    42       50281          0.8                                               1.00           (reference)
  COPD                                                    2532      47      25346    1.9            1.37                                              (1.10--1.70)   
  COPDe                                                   1266      50      12465    4.0            3.73                                              (2.41--5.79)   
  50--59 years                                            No COPD   5292    123      49787          2.5                                               1.00           (reference)
  COPD                                                    2646      79      24917    3.2            1.16                                              (1.00--1.35)   
  COPDe                                                   1323      89      12312    7.2            2.88                                              (2.16--3.86)   
  60--69 years                                            No COPD   5744    263      50401          5.2                                               1.00           (reference)
  COPD                                                    2872      159     26638    6.0            1.04                                              (0.94--1.15)   
  COPDe                                                   1436      119     12363    9.6            1.71                                              (1.35--2.16)   
  70--79 years                                            No COPD   2584    135      17405          7.8                                               1.00           (reference)
  COPD                                                    1292      75      10307    7.3            1.03                                              (0.89--1.19)   
  COPDe                                                   646       50      4518     11.1           1.73                                              (1.23--2.42)   
  0 co-morbidity                                          No COPD   5249    99       40532          2.4                                               1.00           (reference)
  COPD                                                    1284      36      10600    3.4            1.17                                              (0.96--1.45)   
  COPDe                                                   627       37      4744     7.8            2.68                                              (1.74--4.11)   
  1 co-morbidity                                          No COPD   5527    188      49963          3.8                                               1.00           (reference)
  COPD                                                    2279      77      20501    3.8            1.02                                              (0.87--1.19)   
  COPDe                                                   1073      71      8965     7.9            2.52                                              (1.86--3.42)   
  2 co-morbidities                                        No COPD   4219    135      40313          3.3                                               1.00           (reference)
  COPD                                                    2404      98      22626    4.3            1.08                                              (0.95--1.24)   
  COPDe                                                   1200      92      10570    8.7            2.19                                              (1.65--2.90)   
  ≥ 3 co-morbidities                                      No COPD   3689    141      37065          3.8                                               1.00           (reference)
  COPD                                                    3375      149     33481    4.5            1.08                                              (0.97--1.20)   
  COPDe                                                   1771      108     17380    6.2            1.81                                              (1.45--2.26)   

CI = confidence interval; COPD = chronic obstructive pulmonary disease; e = exacerbations; HR = hazard ratio.

^a^Adjusted for all covariates listed in [Table 1](#pone.0181815.t001){ref-type="table"}.

^b^Per 1000 person-years.

^c^Invasive treatments for patients with COPD or COPDe was included.

![Probability of diabetes risk estimated using the Kaplan-Meier method for people with no COPD, COPD, and COPDe.\
Compared with non-COPD cohort or COPD cohort, patients with COPDe showed significantly increased probability of developing diabetes during the follow-up years (log-rank test, p\<0.0001).](pone.0181815.g001){#pone.0181815.g001}

Compared with patients without COPD, diabetic patients with previous COPDe more frequently were male, were older, had low income status, and had higher proportions of hypertension, mental disorders, ischemic heart disease, stroke, heart failure, dementia, hyperlipidemia, anemia, Parkinson's disease, atrial fibrillation, liver cirrhosis, peripheral vascular disease, and renal dialysis ([Table 3](#pone.0181815.t003){ref-type="table"}) (all p\<0.001).

10.1371/journal.pone.0181815.t003

###### Characteristics of hospitalized diabetic patients with and without COPD history.

![](pone.0181815.t003){#pone.0181815.t003g}

                                 No COPD N = 308709   COPD N = 72554   COPDe N = 14253   *P* value                   
  ------------------------------ -------------------- ---------------- ----------------- ----------- ------ -------- ----------
  Gender                         n                    (%)              n                 (%)         N      (%)      \<0.0001
   Female                        131332               (42.5)           31734             (43.7)      5210   (36.6)   
   Male                          177377               (57.5)           40820             (56.3)      9043   (63.4)   
  Age, years                                                                                                         \<0.0001
   40--49                        61709                (20.0)           6285              (8.7)       1002   (7.0)    
   50--59                        97039                (31.4)           14726             (20.3)      2168   (15.2)   
   60--69                        84093                (27.2)           22117             (30.5)      3796   (26.6)   
   70--79                        65868                (21.3)           29426             (40.6)      7287   (51.1)   
  Low income                     13676                (4.4)            4335              (6.0)       1211   (8.5)    \<0.0001
  Co-morbidities                                                                                                     
   Hypertension                  113546               (36.8)           36863             (50.8)      7087   (49.7)   \<0.0001
   Mental disorder               41068                (13.3)           15923             (22.0)      3402   (23.9)   \<0.0001
   Ischemic heart disease        31594                (10.2)           14787             (20.4)      3241   (22.7)   \<0.0001
   Stroke                        30325                (9.8)            10939             (15.1)      2800   (19.6)   \<0.0001
   Heart failure                 4579                 (1.5)            4199              (5.8)       1569   (11.0)   \<0.0001
   Dementia                      4020                 (1.3)            2179              (3.0)       657    (4.6)    \<0.0001
   Hyperlipidemia                26809                (8.7)            8670              (12.0)      1146   (8.0)    \<0.0001
   Anemia                        5203                 (1.7)            2104              (2.9)       429    (3.0)    \<0.0001
   Parkinson\'s disease          2652                 (0.9)            1327              (1.8)       368    (2.6)    \<0.0001
   Atrial fibrillation           1857                 (0.6)            1107              (1.5)       321    (2.3)    \<0.0001
   Liver cirrhosis               7704                 (2.5)            1767              (2.4)       336    (2.4)    0.4085
   Peripheral vascular disease   2365                 (0.8)            945               (1.3)       173    (1.2)    \<0.0001
   Renal dialysis                2610                 (0.9)            623               (0.9)       157    (1.1)    0.0052

COPD = chronic obstructive pulmonary disease; e = exacerbations.

Concerning adverse outcomes during admissions due to diabetes ([Table 4](#pone.0181815.t004){ref-type="table"}), patients with COPDe had a higher risk of pneumonia (OR 3.28, 95% CI 3.13--3.43) and admission to intensive care (OR 1.32, 95% CI 1.26--1.39). Diabetic patients with COPDe had longer length of hospital stays (16.8±66.8 vs. 10.5±48.1 days, p\<0.0001) and higher medical expenditures (2838±8983 vs. 2157±5243 US dollars, p\<0.0001) than those without COPD. Mortality after diabetes hospitalization was also significantly associated with history of COPDe (OR 2.06, 95% CI 1.88--2.25).

10.1371/journal.pone.0181815.t004

###### Outcomes during diabetes hospitalization in patients with COPD.

![](pone.0181815.t004){#pone.0181815.t004g}

                                                               No COPD     COPD        COPDe       Risk for COPD   Risk for COPDe                                         
  ------------------------------------------------------------ ----------- ----------- ----------- --------------- ---------------- -------- ------ -------------- ------ --------------
  Pneumonia                                                    19848       (6.4)       9841        (13.6)          3110             (21.8)   2.04   (1.98--2.10)   3.28   (3.13--3.43)
  ICU                                                          29527       (9.6)       7973        (11.0)          2183             (15.3)   1.01   (0.98--1.04)   1.32   (1.26--1.39)
  Mortality                                                    5114        (1.7)       1778        (2.5)           655              (4.6)    1.23   (1.16--1.30)   2.06   (1.88--2.25)
  ME, US dollars[^b^](#t004fn003){ref-type="table-fn"}         2157±5243   2292±6482   2838±8983   p\<0.0001       p\<0.0001                                              
  Length of stay, days[^b^](#t004fn003){ref-type="table-fn"}   10.5±48.1   11.6±48.8   16.8±66.8   p\<0.0001       p\<0.0001                                              

CI = confidence interval; COPD = chronic obstructive pulmonary disease; e = exacerbation; ME = medical expenditure; OR = odds ratio.

^a^Adjusted for all covariates listed in [Table 3](#pone.0181815.t003){ref-type="table"}.

^b^Mean±SD

The adjusted ORs for COPD patients developing pneumonia after pre-admission for diabetes at 3 months, 6 months, 12 months, and 18 months were 2.77 (95% CI 2.67--2.86), 2.49 (95% CI 2.41--2.57), 2.26 (95% CI 2.20--2.33), and 2.12 (95% CI 2.06--2.18), respectively ([Table 5](#pone.0181815.t005){ref-type="table"}). The risks of mortality and ICU stay associated with COPD also decreased with the time course of COPDe occurrence. Similar results regarding risk of post-diabetes pneumonia, mortality and ICU stay were also found in patients with COPDe. The risk of post-diabetes pneumonia was associated with the occurrences of COPDe within pre-admission for diabetes at 3 months (OR 3.78, 95% CI 3.56--4.02), 6 months (OR 3.46, 95% CI 3.28--3.66), 12 months (OR 3.37, 95% CI 3.21--3.54), and 18 months (OR 3.29, 95% CI 3.13--3.44). The ORs of post-diabetes pneumonia, mortality and ICU stay associated with respiratory invasive treatment in patients with COPDe were 3.30 (95% CI 3.10--3.53), 0.92 (95% CI 0.77--1.10), and 1.52 (95% CI 1.41--1.63), respectively.

10.1371/journal.pone.0181815.t005

###### Time effects of COPD on the outcomes of diabetes admission.

![](pone.0181815.t005){#pone.0181815.t005g}

                             Pneumonia   Mortality   ICU stay                                    
  -------------------------- ----------- ----------- -------------- ------ -------------- ------ --------------
  No COPD                    308709      1.00        (reference)    1.00   (reference)    1.00   (reference)
  COPD occurred                                                                                  
   Pre-admission 3 month     29390       2.77        (2.67--2.86)   1.41   (1.31--1.52)   1.09   (1.05--1.13)
   Pre-admission 6 month     38499       2.49        (2.41--2.57)   1.38   (1.28--1.48)   1.06   (1.02--1.09)
   Pre-admission 12 month    52461       2.26        (2.20--2.33)   1.31   (1.23--1.40)   1.04   (1.00--1.07)
   Pre-admission 18 month    63310       2.12        (2.06--2.18)   1.27   (1.20--1.35)   1.02   (0.99--1.05)
  COPDe occurred                                                                                 
   Pre-admission 3 month     6520        3.78        (3.56--4.02)   2.26   (2.01--2.55)   1.45   (1.36--1.56)
   Pre-admission 6 month     8350        3.46        (3.28--3.66)   2.27   (2.04--2.52)   1.43   (1.35--1.52)
   Pre-admission 12 month    10858       3.37        (3.21--3.54)   2.21   (2.01--2.43)   1.39   (1.31--1.47)
   Pre-admission 18 month    12733       3.29        (3.13--3.44)   2.10   (1.92--2.31)   1.36   (1.29--1.43)
   With invasive treatment   5896        3.30        (3.10--3.53)   0.92   (0.77--1.10)   1.52   (1.41--1.63)

CI = confidence interval; COPD = chronic obstructive pulmonary disease; e = exacerbation; ICU = intensive care unit; OR = odds ratio.

Discussion {#sec012}
==========

Our retrospective cohort study showed that COPD patients with and without exacerbations showed significantly increased risk of developing diabetes compared with those without COPD. The nested cohort study showed diabetic patients with history of COPD were significantly associated with increased pneumonia, admission to intensive care, prolonged length of stay, increased medical expenditure and mortality. The results of our studies were consistent with previous reports. \[[@pone.0181815.ref011]--[@pone.0181815.ref016]\]

Exacerbation is critically important in the natural history and clinical outcome for COPD patients. Our study showed that COPD patients with or without exacerbations were associated with higher risk of developing diabetes, and COPD *per se* impacts diabetes outcomes significantly. Patients experiencing frequent exacerbations were at higher risk for declined lung function and increased mortality \[[@pone.0181815.ref022]--[@pone.0181815.ref024]\]. Previous report also suggested that most COPD exacerbations are due to lower respiratory tract infections \[[@pone.0181815.ref025]\], which significantly worsened outcomes in COPD patients in terms of increased exacerbation rate and mortality \[[@pone.0181815.ref026]\].

Comorbidities including hypertension, hyperlipidemia, stroke and cardiovascular disease were known as independent factors associated with diabetes also commonly coexisting in patients with COPD \[[@pone.0181815.ref005]--[@pone.0181815.ref007],[@pone.0181815.ref011],[@pone.0181815.ref013],[@pone.0181815.ref027]\].To reduce confounding effects, we used multivariate regression models to adjust comorbid conditions and calculated the risk of diabetes in patients with COPD. Age, gender and socioeconomic status were also considered as potential confounding factors associated with COPD and diabetes \[[@pone.0181815.ref012]\]. All these characteristics were adjusted in the multivariate regression models. Although previous cohort studies used nationwide data to analyze the risk of diabetes in COPD patients, they were limited by inadequate adjustment for potential confounders \[[@pone.0181815.ref015],[@pone.0181815.ref016]\]. The present study showed that COPD with exacerbations was associated with risk of developing diabetes in various age groups, co-morbidities and both sexes. However, the association was weaker in subjects with more than three co-morbidities. It is possible that more numerous and complex co-morbidities may dilute the impact of COPD on the risk of diabetes. Compared with non-COPD group, COPDe patients with invasive respiratory treatment did not have increased diabetes risk and post-diabetes mortality in this study. This non-significant association may be due to the beneficial effects of invasive respiratory treatment for patients with COPDe. However, the phenomenon needs future clinical trials for proving the beneficial effects of invasive respiratory treatment.

Although the mechanism for increased risk of diabetes in COPD remains unclear, we suggest that systemic inflammation is a plausible explanation. In patients with COPD, there is much evidence that the serum levels of inflammatory mediators are increased, including tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6) or C reactive protein (CRP) \[[@pone.0181815.ref028],[@pone.0181815.ref029]\]. High levels of TNF-α may interfere with glucose metabolism and insulin sensitivity and increase the risk of new onset diabetes \[[@pone.0181815.ref030], [@pone.0181815.ref031]\]. Elevated levels of IL-6 and CRP have been shown to predict the development of type 2 diabetes \[[@pone.0181815.ref028], [@pone.0181815.ref029]\].

Another possible explanation for increased risk of diabetes in COPD patients might relate to COPD medications. Current international guidelines suggest systemic glucocorticoid therapy, at least a 5-day course, to manage COPD exacerbations \[[@pone.0181815.ref032]\]. Yet prolonged exposure to corticosteroids is known to lead to substantial side effects in COPD patients, even death \[[@pone.0181815.ref033]\]. In addition, steroid therapy for COPD can lead to the development or worsening of diabetes \[[@pone.0181815.ref034],[@pone.0181815.ref035]\], although controversy surrounds this observation \[[@pone.0181815.ref036],[@pone.0181815.ref037]\]. Whether high-dose and/or long-term steroid use in COPD patients causes type 2 diabetes needs further investigation. Oxidative stress is considered an imbalance between oxidants and antioxidants. In COPD patients, either when stable or during exacerbations, oxidative stress was induced mainly by inhaled oxidants such cigarette smoke or pollution \[[@pone.0181815.ref038]\]. Oxidative stress, mainly smoke-induced in COPD patients, could cause insulin resistance in type 2 diabetes \[[@pone.0181815.ref039]\].

A previous study found that diabetes is associated with an increased risk of pulmonary infections, disease exacerbations and worsened COPD outcomes \[[@pone.0181815.ref031]\]. On the other hand, we found that COPD may be considered a novel risk factor for new onset diabetes and this phenomenon may via multiple mechanisms, including steroids therapy and oxidative stress \[[@pone.0181815.ref028],[@pone.0181815.ref029]\]. The further investigation is needed to clarify the link between COPD and diabetes.

This study has some limitations. First, we used insurance claims data that lacked detailed information on sociodemographic and lifestyle factors, hormonal status and biomedical measures \[[@pone.0181815.ref006],[@pone.0181815.ref007]\]. Second, pulmonary function data were not available, so the severity of COPD was not classified using Global Initiative for Obstructive Lung Disease criteria \[[@pone.0181815.ref040]\]. When interpreting the findings of this study should be cautioned because the unavailable data of lung function test is a very important limitation. However, exacerbations are generally considered to become more frequent as the severity of underlying COPD increases \[[@pone.0181815.ref041]\] and findings from this study cannot be compared to those using Global Initiative for Obstructive Lung Disease criteria for disease staging \[[@pone.0181815.ref012],[@pone.0181815.ref040]\]. Third, although we used multivariate adjustment to control for confounders, residual confounding is always possible.

In conclusion, COPD is associated with higher risks of developing diabetes or post-diabetes pneumonia, mortality. However, the real mechanism between COPD and diabetes needs further basic lab data and clinical investigations.

This study is based in part on data obtained from the National Health Insurance Research Database. This database is provided by the Bureau of National Health Insurance of Taiwan's Ministry of Health and Welfare, and is managed by the National Health Research Institutes. The authors' interpretations and conclusions do not represent those of the Bureau of National Health Insurance, the Ministry of Health and Welfare, or the National Health Research Institutes.

CI

:   confidence interval

COPD

:   chronic obstructive pulmonary disease

HR

:   hazard ratio

*ICD-9-CM*

:   *International Classification of Diseases*, *9th Revision*, *Clinical Modification*

OR

:   odds ratio
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